NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy
Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival
OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent
Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study
First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors
Telatinib Demonstrates Positive Results in First-Line Treatment
Barret’s Less of a Risk Factor For Cancer of the Esophagus
New Abiraterone Acetate Results Show Greater Benefit Than Before
MGMT Gene Can Determine Disease Aggressiveness
Phase III Study: Lymphoseek Superior to Vital Blue Dye
Intensity Modulated Therapy Safer Than Three-Dimensional Radiation
Smokers Quitlines Found Effective Regardless of Recruitment Method
Study: Vismodegib Effective Where Surgery is Inappropriate
NCI-Approved Clinical Trials For The Month of June
FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”
FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors
Trending Stories
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- ACOG says it will no longer accept federal funding
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025 - Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death - The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”
